Thane Wettig
Vermogen: 204 190 $ op 30-06-2026
Vermogen: 204 190 $ op 30-06-2026
Thane Wettig is Chief Executive Officer & Director at Kyntra Bio, Inc. since 2023.
Former roles include Chief Commercial Officer at Intarcia Therapeutics, Inc. and Vice President-Diabetes Brands Global Marketing at Lilly Diabetes from 2004 to 2009.
Education includes undergraduate and MBA degrees from Washington University in St. Louis.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
KYNTRA BIO, INC. 0,67% | 06-06-2026 | 27.045 ( 0,67% ) | 204 190 $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| KYNTRA BIO, INC. | Algemeen Directeur | 23-07-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
Lilly Diabetes | Corporate Officer/Principal | 01-01-2009 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops innovative therapies utilizing the Medici drug delivery system | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Washington University in St. Louis
Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FibroGen, Inc.
FibroGen, Inc. Pharmaceuticals: MajorHealth Technology Develops biotechnology-based drugs | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops innovative therapies utilizing the Medici drug delivery system | Health Technology |
Lilly Diabetes |
Kies jouw editie
Alle financiële informatie op nationaal niveau